Other languages InnoCare Pharma Limited

Equities

9969

KYG4783B1032

Market Closed - Hong Kong S.E. Other stock markets 04:08:58 2024-07-11 am EDT			5-day change	1st Jan Change
4.81 ^HKD	+3.44%		-0.82%	-30.19%

Jun. 21	China Grants Priority Review Status for InnoCare's Lymphoma Drug; Shares Jump 6%	MT
Jun. 20	InnoCare Pharma Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

China Grants Priority Review Status for InnoCare's Lymphoma Drug; Shares Jump 6%	Jun. 21
InnoCare Pharma Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China	Jun. 20
InnoCare Pharma Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA	Jun. 11
InnoCare Pharma CEO Boosts Shareholding to 7.16%	May. 31
InnoCare Pharma Grants Over 1.7 Million Shares Under Incentive Scheme	May. 31
InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis	May. 15
Innocare Pharma Posts Q1 Loss	May. 14
InnoCare Logs Loss in Q1	May. 13
InnoCare Pharma Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13
InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib	Mar. 28
InnoCare Pharma Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China	Mar. 12
InnoCare to Shrink Loss in 2023	Jan. 29
InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023	Jan. 29
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China	Jan. 23
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area's Early Access Program	Jan. 21
InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA	Jan. 16
InnoCare Pharma Limited Announces the Positive Top-Line Results from the Phase II Randomized, Double-Blind, Placebo-Controlled Study of ICP-332	Dec. 17
InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH	Dec. 10
InnoCare Pharma Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages InnoCare Pharma Limited

Equities

9969

KYG4783B1032

Other languages

Filters